Clinical Trials · NCT07443826
CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
- Phase
- Phase 1/Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Unlimited Biotechnology LLC
- Enrollment
- 12
- Start date
- Mar 2026
- Locations
- 1 site, Honduras
- Primary endpoint
- Number of participants with treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs)